In honor of #HispanicHeritageMonth, we were delighted to welcome Harlisa Minaya-Ebai, SHRM-CP’s mother to our office to share the flavors of home-cooked Dominican cuisine. Moments like these remind us of the beauty and diversity of Latinx culture, and we’re proud to celebrate the contributions of our Hispanic and Latinx colleagues.
Verve Therapeutics
生物技术研究
Boston,Massachusetts 32,805 位关注者
We are on a mission to protect the world from cardiovascular disease.
关于我们
Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts.
- 网站
-
https://www.vervetx.com
Verve Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Boston,Massachusetts
- 类型
- 私人持股
- 创立
- 2018
地点
-
主要
201 Brookline Ave
Suite 601
US,Massachusetts,Boston,02215
Verve Therapeutics员工
动态
-
In our next segment of Understanding Delivery Systems, we're introducing you to the novel liver delivery system created by our team: the GalNAc-LNP. The GalNAc-LNP was initially developed for our VERVE-201 program to address an important challenge with delivery to the liver in people with homozygous familial hypercholesterolemia (HoFH), since patients with HoFH do not have LDL receptors on the surface of their liver cells, making standard lipid nanoparticle, or #LNP, delivery ineffective. We believe the GalNAc-LNP provides a best-in-class liver delivery system. Learn more in the video below, and reference our website here for additional information:?https://lnkd.in/dPSdQrnW
-
We recently held an employee-led fireside chat about exploring career development opportunities within the workplace. Special thanks to Vervians Ananda Mishra and Zunera Khan for hosting the event and to our panelists for your insights about navigating new professional paths.
-
Cardiovascular disease is the leading cause of death globally, affecting people of all ages, genders, and backgrounds. At Verve, we’re using innovative #geneediting to tackle heart disease at its source, empowering healthier lives for future generations. Hear from our VP of Genomic Medicine Amit Khera, M.D., about the impact you can make on #WorldHeartDay and beyond by raising awareness and promoting the prevention of heart disease. ??
-
Today we’re commemorating Family Heart Foundation’s #FHAwarenessDay. HeFH, or heterozygous familial hypercholesterolemia, an inherited disease characterized by extremely high LDL-C levels in the blood, which can lead to #heartattack and/or stroke at an early age. We have designed a single-course treatment that permanently inactivates the PCSK9 gene in the liver to reduce disease-driving LDL-C and prevent HeFH’s potential life-threatening symptoms. It’s important to #KnowFH to catch diagnosis as early as possible and help lower the risk of heart disease. Learn more here:?https://lnkd.in/gmE_ABQ7?
-
Calling all finance professionals! We’re seeking an Associate Director or Director, Procure to Pay to join our growing team. In this Boston-based hybrid role, you will lead vendor selection, manage and cultivate vendor relationships, and manage competitive negotiations to drive value for Verve and the patients we serve. Learn more about the role here: https://lnkd.in/ed-n_KQG #bostonjobs #financejobs #biotechjobs?
-
High cumulative lifelong exposure to blood cholesterol can clog heart arteries. The solution? Keep blood cholesterol as low as possible for as long as possible. Verve is advancing a pipeline of in vivo #geneediting programs designed to lower cholesterol lifelong after a single treatment. It's important to know your cholesterol levels and take steps to manage them to prevent health complications including heart attack or stroke. During #CholesterolEducationMonth, we encourage you to?speak with your doctor and?check out the resources below?to?take charge of your health. ? American Heart Association:?https://lnkd.in/eDEvGUB ? British Heart Foundation:?https://lnkd.in/gVv-7CQg ? Family Heart Foundation:?https://lnkd.in/gW_YJREh ? Centers for Disease Control and Prevention:?https://lnkd.in/gNxVwdQZ ? National Heart, Lung, and Blood Institute:?https://lnkd.in/gFUrhKS4 ? Heart UK:?https://lnkd.in/g2X95HY?